Latest Clinical News

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer (12-12-2017)

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali® (ribociclib) in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2... Continue Reading

Keytruda Immunotherapy Shows Promise for Patients With Herceptin-resistant Breast Cancer (12-12-2017)

A combination of Keytruda (pembrolizumab) and Herceptin (trastuzumab), tested in patients with Herceptin-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker... Continue Reading

FDA and CMS Collaborate to Make Novel Cancer Biomarker Test Available (12-7-2017)

The U.S. Food and Drug Administration (FDA) has approved the F1CDx biomarker test designed to detect mutations in 324 genes and two genomic signatures in cancer patients. In a truly collaborative effort between the FDA and The Centers for Medicare &... Continue Reading

Managment of the Side Effects of Radiation for Cervical Cancer (12-7-2017)

Radiation therapy, or radiotherapy, is a common way to treat cervical cancer. With any treatment of cancer you must first understand your responsibility and your medical team’s role as well as explore treatment options and get a second opinion(s) before... Continue Reading

Fedratinib May Represent New Option for Jakafi-Resistant Myelofibrosis (12-6-2017)

Patients with myelofibrosis resistant or intolerant to Jakafi (ruxolitinib) may have an alternative treatment option with a novel JAK2-selective inhibitor fedratinib, according to the results of clinical study recently published in the medical journal... Continue Reading

The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer (12-6-2017)

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy – if targeted therapy is not an option immunotherapy... Continue Reading

What You Should Know About the Side Effects of Surgery for Cervical Cancer (12-6-2017)

A hysterectomy is a common surgical treatment of early stage cancer and precancerous disease of the cervix in women. With any treatment of cancer it is important to first understand your responsibility and your medical team’s role as well as explore... Continue Reading

Diagnosed with Esophageal Cancer: 10 Tips on How to Get The Most From Your Doctor (12-1-2017)

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with esophageal cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including... Continue Reading

Understanding Low Back Pain (12-1-2017)

From theSpineCommunity Back pain is a symptom associated with over 60 different medical conditions.  These disorders involve a number of different organ systems.  A variety of healthcare professionals have expertise that can be useful in the diagnosis... Continue Reading

Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia (11-22-2017)

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi®  (ruxolitinib) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant... Continue Reading

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (11-20-2017)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people... Continue Reading

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF) (11-15-2017)

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- “Cutaneous T-cell lymphoma is a blood cancer... Continue Reading

Next Page »